The following figures represent the performance of Green Cross, the leading member of the Green Cross Holdings and holder of the group’s key businesses.
As of 2017, not consolidated
Average rate of growth in company revenue over the past three years8.8%
Average proportion of revenue reinvested in R&D over the past three years11%
Annual rate of increase in the number of employees 1.1%
Annual rate of increase in the number of R&D specialists 5.9%
The highest credit rating given to a Korean pharmaceutical company for its corporate bonds.AA-
Green Cross continues to harness its sales and R&D divisions to ensure continued growth.
Green Cross continues to hire an increasing number of talented research specialists as part of its efforts to strengthen its R&D capabilities.